Alexandra Papadaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandra Papadaki has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anna Batistatou
Department of Pathology, University Hospital of Ioannina, 45500 Ioannina, Greece
1 shared publication - Anna-Lea Amylidi
Department of Medical Oncology, University Hospital of Ioannina, 45500 Ioannina, Greece
1 shared publication - Davide Mauri
Department of Medical Oncology, University Hospital of Ioannina, 45500 Ioannina, Greece
1 shared publication - Evangelos Kolettas
Laboratory of Biology, Faculty of Medicine, School of Health Sciences, Institute of Biosciences, University Centre for Research and Innovation, University of Ioannina, 45110 Ioannina, Greece
1 shared publication - George Pentheroudakis
Department of Medical Oncology, University Hospital of Ioannina, 45500 Ioannina, Greece
1 shared publication - George Zarkavelis
Department of Medical Oncology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece
1 shared publication
Latest Publications
- Open Access
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
Angiogenesis has long been considered to facilitate and sustain cancer growth, making the introduction of anti-angiogenic agents that disrupt the vascular endothelial growth factor/receptor (VEGF/VEGFR) pathway an important milestone at the beginning of the 21st century. Originally research on VEGF signaling focused on its survival and mitogenic effects towards endothelial cells, with moderate so far success of anti-angiogenic therapy. However, VEGF can have multiple effects on additional cell types including immune and tumor cells, by directly influencing and promoting tumor cell survival, proliferation and invasion and contributing to an immunosuppressive microenvironment. In this review, we summarize the effects of the VEGF/VEGFR pathway on non-endothelial cells and the resulting implications of anti-angiogenic agents that include direct inhibition of tumor cell growth and immunostimulatory functions. Finally, we present how previously unappreciated studies on VEGF biology, that have demonstrated immunomodulatory properties and tumor regression by disrupting the VEGF/VEGFR pathway, now provide the scientific basis for new combinational treatments of immunotherapy with anti-angiogenic agents.
Open AccessOld Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
Angiogenesis has long been considered to facilitate and sustain cancer growth, making the introduction of anti-angiogenic agents that disrupt the vascular endothelial growth factor/receptor (VEGF/VEGFR) pathway an important milestone at the beginning of the 21st century. Originally research on VEGF signaling focused on its survival and mitogenic effects towards endothelial cells, with moderate so far success of anti-angiogenic therapy. However, VEGF can have multiple effects on additional cell types including immune and tumor cells, by directly influencing and promoting tumor cell survival, proliferation and invasion and contributing to an immunosuppressive microenvironment. In this review, we summarize the effects of the VEGF/VEGFR pathway on non-endothelial cells and the resulting implications of anti-angiogenic agents that include direct inhibition of tumor cell growth and immunostimulatory functions. Finally, we present how previously unappreciated studies on VEGF biology, that have demonstrated immunomodulatory properties and tumor regression by disrupting the VEGF/VEGFR pathway, now provide the scientific basis for new combinational treatments of immunotherapy with anti-angiogenic agents.